Madrigal press releases are available below. Search them by keyword or browse by date. Year All20262025202420232022202120202019201820172016 May 21, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) May 20, 2026 Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk May 7, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) May 6, 2026 Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates May 5, 2026 Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline April 22, 2026 Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026 April 21, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) April 7, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) March 19, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) March 5, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
May 21, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
May 20, 2026 Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
May 7, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
May 6, 2026 Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
April 22, 2026 Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
April 21, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
April 7, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
March 19, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
March 5, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
